<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179579</url>
  </required_header>
  <id_info>
    <org_study_id>HIPEC-02</org_study_id>
    <nct_id>NCT03179579</nct_id>
  </id_info>
  <brief_title>Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer</brief_title>
  <official_title>A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Systemic Chemotherapy And Cytoreductive Surgery (CRS) in the Treatment of Peritoneal Carcinomatosis From Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shu-Zhong Cui</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is a multi-center, prospective, randomized controlled clinical observation the
      safety and efficacy that stage IV limited peritoneal metastasis of gastric cancer patients
      accept hyperthermic intraperitoneal chemotherapy plus neoadjuvant chemotherapy with CRS and
      systemic chemotherapy. With advanced-stage gastric patients of confined to the peritoneal as
      the research object, with median progression-free survival and overall survival, adverse
      events as the end points.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peritoneal metastases in gastric cancer are considered as terminal disease with poor
      prognosis, the median survival time of this kind of patients is less than 1 year and even
      worse in China. Recently, cytoreductive surgery (CRS) combined with hyperthermic
      intraperitoneal chemotherapy (HIPEC) has been suggested to improve survival in patients with
      peritoneal metastases from gastric cancer. Even though the REGATTA trial demonstrated that
      the removal of the primary tumor is not necessarily beneficial, the role of operation aiming
      at R0 resection combined with new regimens like HIPEC and new chemotherapeutic agents is
      still confusing. Neoadjuvant chemotherapy prolonged OS of patients received macroscopically
      radical (CC0) surgery. Compared to systemic chemotherapy, HIPEC promotes chemotherapy to
      penetrate deeper into the cancer tissue, which needed multicenter randomized clinical trials
      (RCTs) to comfirm. Therefore, we has conducting prospective phase III trial of HIPEC combined
      with systemic chemotherapy and CRS for gastric cancer with peritoneal metastasis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>assess median overall survival rate during 3 years in both study arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk factors for morbidity and mortality</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>determine percent of patients wtih Grade I-IV adverse events according to NCI criteria, Common Terminology Criteria for AE (CTCAE 4.0).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession
2 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks
Cytoreductive surgery
HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession
4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks
Cytoreductive surgery
4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HIPEC with neoadjuvant chemotherapy</intervention_name>
    <description>HIPEC 3 times +NACT 2 cycles +CRS +HIPEC 3 times+ ACT 4-6 cycles</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>CRS with HIPEC and adjuvant cheomtherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Systemic chemotherapy</intervention_name>
    <description>NACT 3 cycles +CRS +ACT 4-6 cycles</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>CRS with systemic chemotherpay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Gastic adenocarcinoma is diagnosed by histological and cytological examination.

          2. Peritoneal carcinomastosis of gastric cancer is diagnosed by laparotomy or
             laparoscopic exploration.

          3. According to Sugarbaker's peritoneal cancer index (PCI), PCI score of participant is
             no more than 20.

          4. 18 &lt; Age &lt; 70 year old

          5. Expected survival &gt; 3 months

          6. Performance status: ECOG 0-1

          7. Adequate bone marrow function Hb ≥9 g/dl (After correction in case of iron deficient
             anemia) WBC ≥ 3,500/mm3, Platelet ≥ 100,000/mm3

          8. Adequate renal function Creatinine ≤ 1.5 mg/dl, and adequate hepatic function
             Bilirubin ≤ 1.5 mg/dl and AST and ALT ≤ 2.5×ULN

        10. Voluntary participation after getting written informed consent.

        Exclusion Criteria:

          1. Except for peritoneal carcinomatosis, gastric cancer concurrently metastasized to
             liver, lung, para-aortic lymph node and other distant organs.

          2. Extensive adhesion in peritoneal cavity

          3. Previous History of other malignancies

          4. Poorly controlled disease e.g. atrial fibrillation, stenocardia, cardiac
             insufficiency, persistent hypertension despite medicinal treatment, ejection
             fraction&lt;50%

          5. Receiving other chemotherapy, radiotherapy or immunotherapy

          6. Patients who are unsuitable candidates by doctor's decision

          7. Without given written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shu-Zhong Cui, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xian-Zi Yang, M.D</last_name>
    <phone>8602066673666</phone>
    <email>7097359@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhen Tang, M.M</last_name>
    <phone>8602066673666</phone>
    <email>tangzhentangmin@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianzi Yang, M.D</last_name>
      <phone>8602066673666</phone>
      <email>7097359@qq.com</email>
    </contact>
    <investigator>
      <last_name>shuzhong cui, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Shu-Zhong Cui</investigator_full_name>
    <investigator_title>President of Affiliated Tumor Hospital of Guangzhou Medical</investigator_title>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Peritoneal Carcinomatosis</keyword>
  <keyword>Hyperthermic Intraperitoneal Chemotherapy</keyword>
  <keyword>Systemic Chemotherapy</keyword>
  <keyword>Cytoreductive Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

